What precautions should I take when taking pemetinib?

Pemigatinib/Pemigatinib is a small molecule kinase inhibitor with anti-tumor activity, Pemigatinib/Pemetinib is indicated for use in patients with fibroblast growth factor receptor2(fgfr 2) Treatment of unresectable locally advanced or metastatic cholangiocarcinoma in adults with previously treated fusions or other rearrangements. It is also indicated for the treatment of adults with FGFR1rearranged relapsed or refractory myeloid/lymphoid neoplasms (MLNs).

What precautions should I take when taking pemetinib?

1.Eye toxicity. Pemetinib/Pemetinib can causeRPED, which may cause symptoms such as blurred vision, visual floaters, or light sensitivity. Pemetinib/Pemetinib’s clinical trials did not include routine monitoring, including optical coherence tomography (O CT) to detect asymptomatic RPED; therefore, the incidence of asymptomatic RPED with sallow disease is unknown. Obtain a comprehensive eye examination, including OCT before starting pemetinib/pemetinib and during treatment During the first 6 months, inspections will be conducted every 2 months, and thereafter every 3 months. For onset of visual symptoms, refer the patient urgently to ophthalmology for evaluation and follow-up every 3 weeks until resolution or discontinuation of pemetinib/pemetinib. Modify dose or permanently discontinue pemetinib as recommended.

2.Hyperphosphatemia and soft tissue mineralization. Can cause hyperphosphatemia, leading to soft tissue mineralization, cutaneous calcification, calcinosis, and non-uremic calcium allergy. The increase in phosphate levels is the pharmacodynamic effect of pemetinib/pemetinib. Monitor for hyperphosphatemia and initiate a low-phosphate diet when serum phosphate level >5.5 mg/dL. In patients with serum phosphate levels >7 mg/dL, initiate phosphate-lowering therapy and withhold, reduce dose, or permanently discontinue pemetinib based on the duration and severity of hyperphosphatemia.

3.Embryo-Fetal Toxicity. Based on the results of animal studies and its mechanism of action, taking pemetinib/pemetinib during pregnancy may cause harm to the fetus. According to13.5 mgArea under the curve (AUC) at mgclinical doses. Oral administration of pemetinib/pemetinib to pregnant rats during the organogenesis period causes fetal malformation, fetal growth retardation, and embryonic-fetal death. Maternal exposure is lower than human exposure. Inform pregnant women of potential risks to the fetus. It is recommended that female patients of childbearing potential use effective contraception during treatment with pemetinib and for 1 week after the last dose. It is recommended that men of childbearing potential who have a female partner use effective contraception during treatment with pemetinib and for 1 week after the last dose. There are generic drugs in Laos, and they are all officially marketed generic drugs with government approval. The retail price of Lucius Pharmaceuticals in Laos is around 1000 yuan for 4.5mg*14 tablets. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0

xa0

xa0